記事

2006年8月17日

Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[Presentation by Daniel Rosan begins at 54:30; refers to Abbott Laboratories, Bristol-Myers Squibb, Merck, Gilead Sciences, Wyeth]

タイムライン

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

日付:

2014年3月4日

コンテンツタイプ:

企業の回答

利用可能言語: English
[PDF] Benchmarking AIDS: 2006 Year End Update

日付:

2006年11月30日

コンテンツタイプ:

記事

利用可能言語: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

日付:

2006年9月13日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

日付:

2006年9月13日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

日付:

2006年9月13日

コンテンツタイプ:

企業の回答

利用可能言語: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

日付:

2006年9月12日

コンテンツタイプ:

記事

利用可能言語: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

日付:

2006年9月6日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

日付:

2006年9月6日

コンテンツタイプ:

企業の回答

利用可能言語: English
Reclaman mayor compromiso de las farmacéuticas

日付:

2006年8月31日

コンテンツタイプ:

記事

利用可能言語: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

日付:

2006年8月23日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

日付:

2006年8月23日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

日付:

2006年8月23日

コンテンツタイプ:

企業の回答

利用可能言語: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

日付:

2006年8月17日

コンテンツタイプ:

記事

利用可能言語: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

日付:

2006年8月17日

コンテンツタイプ:

記事

利用可能言語: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

日付:

2006年8月14日

コンテンツタイプ:

記事

利用可能言語: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

日付:

2006年8月1日

コンテンツタイプ:

企業の回答

利用可能言語: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

日付:

2006年8月1日

コンテンツタイプ:

企業の回答

利用可能言語: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

日付:

2006年1月8日

コンテンツタイプ:

企業の回答

利用可能言語: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

日付:

2006年1月8日

コンテンツタイプ:

企業の回答

利用可能言語: English

ストーリー全体を見る

さらに読み込む表示を減らす

Business & Human Rights
Resource Centre

月刊ニュースレター2024年11月号

月刊ニュースレター2024年10月号

ビジネスと人権リソースセンター

月刊ニュースレター2024年11月号

月刊ニュースレター2024年10月号

このページは日本語では利用できません。English で表示されています

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

タイムライン

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

月刊ニュースレター2024年11月号

月刊ニュースレター2024年10月号

月刊ニュースレター2024年11月号

月刊ニュースレター2024年10月号

このページは 日本語 では利用できません。English で表示されています

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

タイムライン

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

このページは日本語では利用できません。English で表示されています